Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind and Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Moderate to Severe Atopic Dermatitis

Next Previous
Trial Profile

A Randomized, Double-Blind and Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Moderate to Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivarmacitinib (Primary) ; Ivarmacitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms QUARTZ2
  • Sponsors Reistone Biopharma

Most Recent Events

  • 09 Aug 2021 Results published in the American Journal of Clinical Dermatology.
  • 13 May 2021 According to a Reistone Biopharma media release, data from this trial were presented as a late breaking abstract in AAD VMX meeting 2021.
  • 29 Oct 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top